Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | DRD4 | P21917 | 7/20 | 0.47 |
| ▸ | DRD3 | P35462 | 7/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882579 | 1.00 | S1PR5 (0.48) | S1PR5S1PR1DRD2DRD4DRD3 | |
| SCHEMBL875727 | 1.00 | S1PR5 (0.48) | S1PR5S1PR1DRD2DRD4DRD3 | |
| SCHEMBL874431 | 1.00 | S1PR5 (0.48) | S1PR5S1PR1DRD2DRD4DRD3 | |
| SCHEMBL6232439 | 0.91 | S1PR5 (0.53) | S1PR5S1PR1FUCA1SIGMAR1 | |
| SCHEMBL585357 | 0.91 | S1PR5 (0.53) | S1PR5S1PR1FUCA1SIGMAR1 | |
| SCHEMBL585358 | 0.91 | S1PR5 (0.53) | S1PR5S1PR1FUCA1SIGMAR1 | |
| SCHEMBL6232433 | 0.91 | S1PR5 (0.53) | S1PR5S1PR1FUCA1SIGMAR1 | |
| SCHEMBL1282973 | 0.88 | S1PR5 (0.53) | S1PR5DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL19064205 | 0.87 | S1PR5 (0.52) | S1PR5S1PR1FUCA1SIGMAR1 | |
| SCHEMBL9112639 | 0.87 | S1PR5 (0.52) | S1PR5S1PR1FUCA1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3181566-A1 | IMIDAZOTRIAZINONE COMPOUNDS | Ironwood Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2012040230-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-2152712-B1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER (US) | 2012-01-11 | — | — | EP | disclosed |
| US-7964607-B2 | Pyrazolo[3,4-d]pyrimidine compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964607-B2 | Pyrazolo[3,4-d]pyrimidine compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964607-B2 | Pyrazolo[3,4-d]pyrimidine compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2152712-A1 | AMINO-HETEROCYCLIC COMPOUNDS | Pfizer Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| WO-2008139293-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE12, PDE4A | S1PR5 1335/4885S1PR1 1663/4885DRD2 3800/4885 |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | S1PR5 3767/4885S1PR1 3298/4885DRD2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.